Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct 17;2007(4):CD005324.
doi: 10.1002/14651858.CD005324.pub2.

Bisphosphonate therapy for children and adolescents with secondary osteoporosis

Affiliations
Review

Bisphosphonate therapy for children and adolescents with secondary osteoporosis

L Ward et al. Cochrane Database Syst Rev. .

Abstract

Background: Children with chronic illnesses are at increased risk for reductions in bone strength and subsequent fractures (osteoporosis), either due to the impact of the underlying condition on skeletal development or due to the osteotoxic effect of medications (e.g., glucocorticoids) used to treat the chronic illness. Bisphosphonates are being administered with increasing frequency to children with secondary osteoporosis; however, the efficacy and harm of these agents remains unclear.

Objectives: To examine the efficacy and harm of bisphosphonate therapy in the treatment and prevention of secondary osteoporosis in children and adolescents.

Search strategy: We searched the Cochrane Central Register of Controlled Trials (Issue 4, 2006), MEDLINE, EMBASE, CINAHL and ISI Web of Science (inception-December 2006). Further literature was identified through expert contact, key author searches, scanning reference lists of included studies, and contacting bisphosphonate manufacturers.

Selection criteria: Randomized, quasi-randomized, controlled clinical trials, cohort, and case controls of bisphosphonate(s) in children 0-18 years of age with at least one low-trauma fracture event or reductions in bone mineral density in the context of secondary osteoporosis.

Data collection and analysis: Two reviewers independently extracted data and assessed quality. Case series were used for supplemental harms-related data.

Main results: Six RCTs, two CCTs, and one prospective cohort (n=281 children) were included and classified into osteoporosis due to: 1) neuromuscular conditions (one RCT) and 2) chronic illness (five RCTs, two CCTs, one cohort). Bisphosphonates examined were oral alendronate, clodronate, and intravenous (IV) pamidronate. Study quality varied. Harms data from 23 case series (n=241 children) were used. Heterogeneity precluded statistically combining the results. Percent change or Z-score change in lumbar spine areal BMD from baseline were consistently reported. Two studies carried out between-group analyses; one showed no significant difference (using oral alendronate in anorexia nervosa) while the other demonstrated a treatment effect on lumbar spine with IV pamidronate in burn patients. Frequently reported harms included the acute phase reaction, followed by gastrointestinal complaints, and bone/muscle pain.

Authors' conclusions: The results justify further evaluation of bisphosphonates among children with secondary osteoporosis. However, the evidence does not support bisphosphonates as standard therapy. Short-term (3 years or less) bisphosphonate use appears to be well-tolerated. An accepted criterion for osteoporosis in children, a standardized approach to BMD reporting, and examining functional bone health outcomes (e.g., fracture rates) will allow for appropriate comparisons across studies.

PubMed Disclaimer

Conflict of interest statement

Leanne Ward and Frank Rauch have been co‐applicants in the past on operating grants from Merck‐Frost & Co to study alendronate, Novartis to study zoledronate and Proctor and Gamble to study risedronate, among patients with OI. Dr. Ward has also been a site investigator on an operating grant from Merck‐Frost & Co to investigate the pharmacokinetics and safety of alendronate among children with steroid‐induced osteoporosis.

Andrea C. Tricco has been a paid consultant for GlaxoSmithKline's non‐bisphosphonate related products.

Phuc‐Nhi Phuong ‐ none declared.

Ann Cranney has been a Consultant on the Merck Osteoporosis Medical Advisory Board and has received research funds from Merck for research to evaluate care gap in the treatment of older adults with fractures.

Nick Barrowman ‐ none declared.

Isabelle Gaboury ‐ none declared.

Peter Tugwell has been a paid consultant for Merck Frost. Please see the CMSG website www.cochranemsk.org for a detailed declaration of interest statement.

David Moher ‐ none declared.

Figures

1
1
1.1
1.1. Analysis
Comparison 1 lumbar spine, Outcome 1 lumbar spine.

Update of

  • doi: 10.1002/14651858.CD005324

Similar articles

Cited by

References

References to studies included in this review

Acott 2005 {published data only}
    1. Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatric Nephrology 2005;20(3):368‐73. - PubMed
Bianchi 2000 {published data only}
    1. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis & Rheumatism 2000;43(9):1960‐6. - PubMed
El‐Husseini 2004 {published data only}
    1. El‐Husseini AA, El‐Agroudy AE, El‐Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatric Transplant 2004;8(4):357‐61. - PubMed
Golden 2005 {published data only}
    1. Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism 2005;90(6):3179‐85. - PubMed
Henderson 2002 {published data only}
    1. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo‐controlled clinical trial. Journal of Pediatrics 2002;141(5):644‐51. - PubMed
Kim 2006 {published data only}
    1. Kim S‐D, Cho B‐S. Pamidronate therapy for preventing steroid‐induced osteoporosis in children with nephropathy. Nephron Clinical Practice 2006;102:c81. - PubMed
Klein 2005 {published data only}
    1. Klein GL, Wimalawansa SJ, Kulkarni G, Sherrard DJ, Sanford AP, Herndon DN. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double‐blind, randomized, controlled study. Osteoporosis International 2005;16(6):631‐5. - PubMed
Lepore 1991 {published data only}
    1. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clinical and Experimental Rheumatology 1991;9(Suppl 6):33‐5. - PubMed
Rudge 2005 {published data only}
    1. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once‐weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005;44(6):813‐8. - PubMed

References to studies excluded from this review

Brown 2005 {published data only}
    1. Brown JJ, Zacharin MR. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid‐induced osteoporosis in children and adolescents. Journal of Paediatrics and Child Health 2005;41(11):580‐2. - PubMed

References to ongoing studies

Crabtree {unpublished data only}
    1. Bone density changes following liver transplantation in children. A RCT of a single dose of intravenous pamidronate. Ongoing study Not reported.
Langman {unpublished data only}
    1. Bone after cessation of alendronate use in children with fracturing osteoporosis. Ongoing study 2003.
Langman CB {unpublished data only}
    1. Restoration and Maintenance of Bone Density with alendronate in children with osteoporosis or The effects of alendronate in the treatment and follow‐up of osteoporosis in children of normal stature. Ongoing study Not reported.
von Scheven {unpublished data only}
    1. Predicting low bone mineral density in childhood inflammatory diseases: Experience from a glaser pediatric research network alendronate trial. Ongoing study Not reported.

Additional references

Albrecht 2005
    1. Albrecht J, Meves A, Bigby M. Case reports and case series from Lancet had significant impact on medical literature. Journal of Clinical Epidemiology 2005;58(12):1227‐32. - PubMed
Allington 2005
    1. Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta orthopaedica Belgica 2005;71(1):91‐7. - PubMed
Bachrach 2006
    1. Bachrach SJ, Kecskemethy HH, Harcke HT, Lark RK, Miller F, Henderson RC. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. Journal of Clinical Densitometry 2006;9(2):167‐74. - PubMed
Barr 2002
    1. Barr RD, Guo CY, Wiernikowski J, Webber C, Wright M, Atkinson S. Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with Pamidronate. Medical and Pediatric Oncology 2002;39(1):44‐6. - PubMed
Batch 2003
    1. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. Journal of Pediatrics and Child Health 2003;39(2):88‐92. - PubMed
Berlin 1997
    1. University of Pennsylvania Meta‐analysis blinding study group. Dose blinding of readers affect the results of meta‐analyses. The Lancet 1997;350:185‐6. - PubMed
Boers 2005
    1. Boers M, Brooks P, Simon LS, Strand V, Tugwell P. OMERACT: an international initiative to improve outcome measurement in rheumatology. Clinical and experimental rheumatology 2005;23(5 Suppl 39):S10‐3. - PubMed
Borzutzky 2006
    1. Borzutzky, A, Reyes, M.L, Figueroa, V, Garcia, C, Cavieres, M. Osteoporosis in children with severe congenital neutropenia: bone mineral density and treatment with bisphosphonates. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2006;28(4):205‐9. - PubMed
Carter 1992
    1. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. Journal of Bone and Mineral Research 1992;7(2):137‐45. - PubMed
Chan 2005
    1. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365(9465):1159‐62. - PubMed
Cimaz 2002
    1. Cimaz R, Gattorno M, Sormani MP, Falcini F, Zulian F, Lepore L, Bardare M, Chiesa S, Corona F, Dubini A, Lenhardt A, Martini G, Masi L, Bianchi ML. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. Journal of Rheumatology 2002;29(8):1786‐92. - PubMed
Clark 2006
    1. Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta‐analysis. Pediatrics 2006;117(2):e291‐7. - PMC - PubMed
Cranney 1999
    1. Cranney A, Welch V, Tugwell P, Wells G, Adachi JD, McGowan J, Shea B. Responsiveness of endpoints in osteoporosis clinical trials ‐ an update. Journal of Rheumatology 1999;26(1):222‐8. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629‐34. - PMC - PubMed
Falcini 1996
    1. Falcini F, Trapani S, Ermini M, Brandi ML. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcified Tissue International 1996;58(3):166‐9. - PubMed
Fernandes 2004
    1. Fernandes JL, Viana SL, Rocha AL, Ribeiro MC, Castro LC. Biphosphonate‐induced radiographic changes in two pediatric patients with rheumatic diseases. Skeletal radiology 2004;33(12):732‐6. - PubMed
Fleisch 1998
    1. Fleisch H. Bisphosphonates: mechanism of action. Endocrine Review 1998;19(1):80‐100. - PubMed
Gandrud 2003
    1. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low‐dose intravenous pamidronate reduces fractures in childhood osteoporosis. Journal of Pediatric Endocrinology and Metabolism 2003;16(6):887‐92. - PubMed
Genant 1999
    1. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task‐Force for Osteoporosis. Osteoporosis International 1999;10(4):259‐64. - PubMed
Glorieux 1998
    1. Glorieux FH, Bishop N, Plotkin H, Chabot G, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New England Journal of Medicine 1998;339:947‐52. - PubMed
Goldbloom 2005
    1. Goldbloom EB, Cummings EA, Yhap M. Osteoporosis at presentation of childhood ALL: management with pamidronate. Pediatric hematology and oncology 2005;22(7):543‐50. - PubMed
Halton 1996
    1. Halton JM, Atkinson SA, Faher L, Webber C, Gill GJ, Dawson S, Barr RD. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. Journal of Bone and Mineral Research 1996;11(11):1774‐83. - PubMed
Hawker 2005
    1. Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD. Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation 2005;86(2):284‐8. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. British Medical Journal 2003;327:557‐60. - PMC - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2005; Vol. 2005, issue 3.
Hogler 2004
    1. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short‐term safety assessment in the use of intravenous zoledronic acid in children. Journal of Pediatrics 2004;145(5):701‐4. - PubMed
Jadad 1996
    1. Jadad A, Moore A, Carrol D, et al. Assessing the quality of randomized trials: Is blinding necessary. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Kanumakala 2002
    1. Kanumakala S, Boneh A, Zacharin M. Pamidronate treatment improves bone mineral density in children with Menkes disease. Journal of Inherited Metabolic Disease 2002;25(5):391‐8. - PubMed
Kotaniemi 1999
    1. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Weight‐bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scandinavian Journal of Rheumatology 1999;28(1):19‐26. - PubMed
Kroger 1992
    1. Kroger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by dual‐energy x‐ray absorptiometry. Bone and Mineral 1992;17(1):75‐85. - PubMed
Land 2006a
    1. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment. Bone 2006;39:901‐6. - PubMed
Land 2006b
    1. Land C, Rauch F, Montpetit K, Ruck‐Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. Journal of Pediatrics 2006;148:456‐60. - PubMed
Lettgen 1994
    1. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatric Nephrology 1994;8(6):667‐70. - PubMed
Lucarelli 2006
    1. Lucarelli S, Borrelli O, Paganelli M, Capocaccia P, Frediani T, Ferri F, Cucchiara S. Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate. Journal of pediatric gastroenterology and nutrition 2006;43(4):533‐5. - PubMed
Munns 2004
    1. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long‐term pamidronate treatment before conception: a report of two cases. Journal of Bone and Mineral Research 2004;19(10):1742‐5. - PubMed
NIH Consens 2001
    1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2001; Vol. 17, issue 1:1‐45. - PubMed
Noguera 2003
    1. Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M, Gonzalez E. Bisphosphonates, a new treatment for glucocorticoid‐induced osteoporosis in children. Journal of Pediatric Endocrinology and Metabolism 2003;16(4):529‐36. - PubMed
Plotkin 2000
    1. Plotkin H, Rauch F, Bishop N, Montpetit K, Ruck‐Gibbis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under three years of age. Journal of Clinical Endocrinology and Metabolism 2000;85(5):1846‐50. - PubMed
Plotkin 2006
    1. Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G, Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Developmental medicine and child neurology 2006;48(9):709‐12. - PubMed
Rauch 2002
    1. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation 2002;110(9):1293‐9. - PMC - PubMed
Rauch 2003
    1. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. Journal of Bone and Mineral Research 2003;18(4):610‐4. - PubMed
Rauch 2006a
    1. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. Journal of Clinical Endocrinology Metabolism 2006;91:1268‐74. - PubMed
Rauch 2006b
    1. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long‐term therapy. Journal of Clinical Edocrinology Metabolism 2006;91:511‐6. - PubMed
Ray 1997
    1. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997;12(1):24‐35. - PubMed
Rosen 1996
    1. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996;51(4):537‐51. - PubMed
Samuel 1994
    1. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 1994;94(3):385‐9. - PubMed
Schultz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Sekhar 2001
    1. Sekhar RV, Culbert S, Hoots WK, Klein MJ, Zietz H, Vassilopoulou‐Sellin R. Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony‐stimulating factor: suggested therapeutic approach. Pediatrics 2001;108(3):E54. - PubMed
Sellers 1998
    1. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatric nephrology (Berlin, Germany) 1998;12(9):778‐81. - PubMed
Shaw 1994
    1. Shaw NJ, White CP, Fraser WD, Rosenbloom L. Osteopenia in cerebral palsy. Archives of Disese in Childhood 1994;71(3):235‐8. - PMC - PubMed
Shaw 2000
    1. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Archives of Disease in Childhood 2000;71(3):143‐5. - PMC - PubMed
Shoemaker 1999
    1. Shoemaker L. Expanding role of bisphosphonate therapy in children. Journal of Pediatrics 1999;134(3):264‐7. - PubMed
Sholas 2005
    1. Sholas MG, Tann B, Gaebler‐Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. Journal of pediatric orthopedics 2005;25(3):326‐31. - PubMed
Strauss 2001
    1. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bone morbidity in children treated for acute lymphoblastic leukemia. Journal of Clinical Oncology 2001;19(12):3066‐72. - PubMed
Sumnik 2004
    1. Sumnik Z, Land C, Rieger‐Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. Hormone Research 2004;61:137‐42. - PubMed
Tenbrock 2000
    1. Tenbrock K, Kruppa S, Mokov E, Querfeld U, Michalk D, Schoenau E. Analysis of muscle strength and bone structure in children with renal disease. Pediatric Nephrology 2000;14(7):669‐72. - PubMed
Tragiannidis 2006
    1. Tragiannidis A, Athanassiadou F, Papageorgiou T, Petsatodis G. Severe skeletal complications in a child with acute lymphoblastic leukemia. Pediatric hematology and oncology 2006;23(6):523‐5. - PubMed
Tugwell 2004
    1. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (editors). Evidence‐based Rheumatology. London: BMJ Books, 2004.
US Dept Health 2004
    1. US Department of Health and Human Service Public Health Service. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Executive Summary. URL: http://www.surgeongeneral.gov/library/bonehealth/docs/exec_summ.pdf. Rockville, MD, 2004.
Van den Wyn. 2006
    1. Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy. Annals of Oncology Aug 2006;17(8):1197‐204. - PubMed
Ward 2003
    1. Ward LM, Glorieux FH. The Spectrum of Osteoporosis. In: F.H. Glorieux, H. Juppner, J. Pettifor editor(s). Pediatric Bone Biology and Diseases. 1. Elsevier Science, 2003:401‐42.
Wells Unpub
    1. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of non‐randomized studies in meta‐analyses. URL: http://www.ohri.ca/.. Ottawa.
Wiernikowski 2005
    1. Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA. Alendronate for steroid‐induced osteopenia in children with acute lymphoblastic leukaemia or non‐Hodgkin's lymphoma: results of a pilot study. Journal of Oncology Pharmacy Practice 2005;11(2):51‐6. - PubMed

MeSH terms

Substances